Skip to main content
OpenTrials
Completed

NCT Number: NCT01887197

Repeatability and Response Study of Absorptive Clearance Scans

The investigators are developing a new nuclear medicine imaging technique for measuring liquid absorption in the airways that can be applied to screen new medications being developed to treat cystic fibrosis (CF). The investigators believe that the absorption of the small molecule radiopharmaceutical Indium 111 diethylene triamine pentaacetic acid (In-DTPA) will indicate changes in liquid absorption in the airways and demonstrate whether new CF medications will be effective. In this study the investigators will determine whether the imaging technique will demonstrate similar results when it is repeated on different days. They will also determine how their results change when subjects utilize several common CF medications.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States

About this study

Cystic Fibrosis (CF) is an autosomal recessive genetic disease, caused by mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) that impairs ion transport at epithelial surfaces. This results in the accumulation of dehydrated secretions in the airways and chronic infection and inflammation in the lungs, leading to significant morbidity and mortality. The investigators understanding of CF pathogenesis has increased substantially and many new targeted therapies are being developed to treat this disease, however, the measurements of clinical efficacy used to evaluate these therapies require long trials to demonstrate an effect. New translational techniques are needed to assess changes in the most basic aspects of the disease and allow for the rapid screening of disease-altering therapies. The investigators have recently developed a novel aerosol-based imaging technique to measure liquid absorption in the airways - a central pathophysiological process related to CFTR dysfunction. The investigators propose that airway liquid hyper-absorption is a key link between cellular defects in ion and fluid transport and progressive airway dysfunction in CF. Thus The investigators technique may provide a measure of disease severity and rapid indication of therapeutic correction in advance of currently available outcome measures.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • subjects 18 years old or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator

Exclusion criteria

  • one second forced expiratory volume (FEV1) <50% of predicted
  • nursing mother
  • positive urine pregnancy test or unwilling to test
  • cigarette smoker
  • unwilling to stop hypertonic saline therapy for 72 hours prior to each test day
  • are intolerant to hypertonic saline (response only)
  • are intolerant to any inhaled therapies (response only)
  • fail mannitol tolerance testing (response only)
  • have a history of excessive (uncontrollable) coughing after an osmotic stimulus (response only)
  • have a history of hemoptysis (response only)

Treatment and study plan

Absorptive clearance scan

Other

Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.

inhaled hypertonic saline (7%)

Drug

nebulized hypertonic saline (7%)

Other names: Hypersal

mannitol inhalation powder

Drug

mannitol inhalation powder

Other names: Bronchitol

Primary outcomes

  1. absorptive clearance variability

    Time frame: 30 days

    The difference in absorptive clearance measured on two different study days in the same subjects as an indicator of measurement variability

  2. absorptive clearance response

    Time frame: 14 day

    The change in absorptive clearance demonstrated in response to therapy when compared to baseline

Sponsors and collaborators

Lead sponsor

Tim Corcoran

Other

Registry information

Important dates

Study start
2013
Primary completion
2017
Study completion
2018
First posted
Jun 26, 2013
Registry last updated
Nov 6, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.